Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atacicept in Subjects With IgA Nephropathy (ORIGIN 3)
NCT04716231Phase 3Active, not recruiting
- Sponsor
- Vera Therapeutics
- Start
- Jun 2023
- Primary completion
- May 2025
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 3 trial of atacicept in IgA nephropathy (IgAN), sponsored by Vera Therapeutics. Started Jun 2023; status: active, not recruiting.
02
Drugs
atacicept
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on NCT04716231.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04716231.